Which has stronger valuation and earnings, QSI or HYFT?

MindWalk has higher revenue and earnings than Quantum-Si. MindWalk is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum-Si $1.61M 98.87 -$101.34M -$0.46 N/A MindWalk $15.56M 3.99 -$10.11M -$0.22 N/A

Is QSI or HYFT more profitable?

MindWalk has a net margin of -89.65% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Quantum-Si -6,138.26% -47.12% -43.18% MindWalk -89.65% -92.61% -54.15%

Does the media prefer QSI or HYFT?

In the previous week, MindWalk had 9 more articles in the media than Quantum-Si. MarketBeat recorded 15 mentions for MindWalk and 6 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.52 beat MindWalk's score of -0.08 indicating that Quantum-Si is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum-Si 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CDXS or HYFT?

MindWalk has lower revenue, but higher earnings than Codexis. MindWalk is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $77.68M 2.09 -$43.97M -$0.34 N/A MindWalk $15.56M 3.99 -$10.11M -$0.22 N/A

Is CDXS or HYFT more profitable?

Codexis has a net margin of -39.55% compared to MindWalk's net margin of -89.65%. Codexis' return on equity of -74.36% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% MindWalk -89.65% -92.61% -54.15%

Does the media favor HYFT or NAUT?

In the previous week, MindWalk had 10 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 15 mentions for MindWalk and 5 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.58 beat MindWalk's score of -0.08 indicating that Nautilus Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Nautilus Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MXCT or HYFT?

MindWalk has lower revenue, but higher earnings than MaxCyte. MindWalk is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 3.67 -$44.63M -$0.33 N/A MindWalk $15.56M 3.99 -$10.11M -$0.22 N/A

Is MXCT or HYFT more profitable?

MindWalk has a net margin of -89.65% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -114.77% -18.92% -16.14% MindWalk -89.65% -92.61% -54.15%

Does the media refer more to MXCT or HYFT?

In the previous week, MindWalk had 13 more articles in the media than MaxCyte. MarketBeat recorded 15 mentions for MindWalk and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.93 beat MindWalk's score of -0.08 indicating that MaxCyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, HYFT or QTRX?

MindWalk has higher earnings, but lower revenue than Quanterix. MindWalk is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MindWalk $15.56M 3.99 -$10.11M -$0.22 N/A Quanterix $138.90M 0.85 -$107.15M -$2.63 N/A

Is HYFT or QTRX more profitable?

Quanterix has a net margin of -80.25% compared to MindWalk's net margin of -89.65%. Quanterix's return on equity of -26.09% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -89.65% -92.61% -54.15% Quanterix -80.25% -26.09% -19.03%

Does the media prefer HYFT or QTRX?

In the previous week, MindWalk had 12 more articles in the media than Quanterix. MarketBeat recorded 15 mentions for MindWalk and 3 mentions for Quanterix. Quanterix's average media sentiment score of 0.62 beat MindWalk's score of -0.08 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MindWalk (HYFT) Competitors

$1.33 +0.03 (+1.92%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$1.24 -0.09 (-7.07%)

As of 06:17 AM Eastern

Compare

HYFT vs. QSI, CDXS, NAUT, MXCT, and QTRX

Should you buy MindWalk stock or one of its competitors? MindWalk's main competitors and comparable companies include Quantum-Si (QSI), Codexis (CDXS), Nautilus Biotechnology (NAUT), MaxCyte (MXCT), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MindWalk compare to Quantum-Si?

Quantum-Si (NASDAQ:QSI) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

In the previous week, MindWalk had 9 more articles in the media than Quantum-Si. MarketBeat recorded 15 mentions for MindWalk and 6 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.52 beat MindWalk's score of -0.08 indicating that Quantum-Si is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum-Si	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 22.0% of Quantum-Si shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Quantum-Si has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Quantum-Si currently has a consensus price target of $1.00, indicating a potential upside of 37.93%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 275.94%. Given MindWalk's stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

MindWalk has higher revenue and earnings than Quantum-Si. MindWalk is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$1.61M	98.87	-$101.34M	-$0.46	N/A
MindWalk	$15.56M	3.99	-$10.11M	-$0.22	N/A

MindWalk has a net margin of -89.65% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,138.26%	-47.12%	-43.18%
MindWalk	-89.65%	-92.61%	-54.15%

Summary

MindWalk beats Quantum-Si on 9 of the 17 factors compared between the two stocks.

How does MindWalk compare to Codexis?

Codexis (NASDAQ:CDXS) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

78.5% of Codexis shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Codexis has a net margin of -39.55% compared to MindWalk's net margin of -89.65%. Codexis' return on equity of -74.36% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
MindWalk	-89.65%	-92.61%	-54.15%

Codexis has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

In the previous week, MindWalk had 14 more articles in the media than Codexis. MarketBeat recorded 15 mentions for MindWalk and 1 mentions for Codexis. Codexis' average media sentiment score of 1.87 beat MindWalk's score of -0.08 indicating that Codexis is being referred to more favorably in the media.

Company	Overall Sentiment
Codexis	Very Positive
MindWalk	Neutral

Codexis presently has a consensus target price of $6.50, suggesting a potential upside of 339.19%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 275.94%. Given Codexis' higher probable upside, equities analysts clearly believe Codexis is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

MindWalk has lower revenue, but higher earnings than Codexis. MindWalk is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$77.68M	2.09	-$43.97M	-$0.34	N/A
MindWalk	$15.56M	3.99	-$10.11M	-$0.22	N/A

Summary

Codexis beats MindWalk on 9 of the 16 factors compared between the two stocks.

How does MindWalk compare to Nautilus Biotechnology?

MindWalk (NASDAQ:HYFT) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

MindWalk has higher revenue and earnings than Nautilus Biotechnology. MindWalk is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$15.56M	3.99	-$10.11M	-$0.22	N/A
Nautilus Biotechnology	$10K	11,533.12	-$59M	-$0.45	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to MindWalk's net margin of -89.65%. Nautilus Biotechnology's return on equity of -37.58% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-89.65%	-92.61%	-54.15%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

6.7% of MindWalk shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MindWalk has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

MindWalk presently has a consensus price target of $5.00, indicating a potential upside of 275.94%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 341.35%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, MindWalk had 10 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 15 mentions for MindWalk and 5 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.58 beat MindWalk's score of -0.08 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nautilus Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nautilus Biotechnology beats MindWalk on 10 of the 16 factors compared between the two stocks.

How does MindWalk compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

MindWalk has a net margin of -89.65% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
MindWalk	-89.65%	-92.61%	-54.15%

MindWalk has lower revenue, but higher earnings than MaxCyte. MindWalk is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.67	-$44.63M	-$0.33	N/A
MindWalk	$15.56M	3.99	-$10.11M	-$0.22	N/A

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, MindWalk had 13 more articles in the media than MaxCyte. MarketBeat recorded 15 mentions for MindWalk and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.93 beat MindWalk's score of -0.08 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

MaxCyte presently has a consensus target price of $5.00, suggesting a potential upside of 325.53%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 275.94%. Given MaxCyte's higher possible upside, analysts clearly believe MaxCyte is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

MaxCyte has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Summary

MindWalk beats MaxCyte on 9 of the 17 factors compared between the two stocks.

How does MindWalk compare to Quanterix?

MindWalk (NASDAQ:HYFT) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Quanterix has a net margin of -80.25% compared to MindWalk's net margin of -89.65%. Quanterix's return on equity of -26.09% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-89.65%	-92.61%	-54.15%
Quanterix	-80.25%	-26.09%	-19.03%

MindWalk has higher earnings, but lower revenue than Quanterix. MindWalk is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$15.56M	3.99	-$10.11M	-$0.22	N/A
Quanterix	$138.90M	0.85	-$107.15M	-$2.63	N/A

MindWalk has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

MindWalk currently has a consensus price target of $5.00, suggesting a potential upside of 275.94%. Quanterix has a consensus price target of $3.00, suggesting a potential upside of 20.00%. Given MindWalk's stronger consensus rating and higher possible upside, research analysts plainly believe MindWalk is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, MindWalk had 12 more articles in the media than Quanterix. MarketBeat recorded 15 mentions for MindWalk and 3 mentions for Quanterix. Quanterix's average media sentiment score of 0.62 beat MindWalk's score of -0.08 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

MindWalk beats Quanterix on 9 of the 17 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.96M	$9.75B	$7.16B	$14.30B
Dividend Yield	N/A	1.48%	2.57%	11.70%
P/E Ratio	-6.05	67.70	273.30	25.37
Price / Sales	3.99	267.24	650.46	87.69
Price / Cash	N/A	26.35	28.42	34.96
Price / Book	7.39	5.38	10.48	6.24
Net Income	-$10.11M	$56.67B	$3.49B	$358.08M
7 Day Performance	-1.48%	-0.29%	-1.09%	-0.70%
1 Month Performance	-5.67%	0.15%	0.63%	-2.76%
1 Year Performance	N/A	25.12%	20.22%	6.72%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	2.3496 of 5 stars	$1.33 +1.9%	$5.00 +275.9%	N/A	$60.96M	$15.56M	N/A	80	Trending News Earnings Report High Trading Volume
QSI Quantum-Si	2.6514 of 5 stars	$0.75 +1.6%	$1.00 +33.2%	-38.6%	$163.94M	$2.44M	N/A	150	Analyst Upgrade
CDXS Codexis	3.1324 of 5 stars	$1.47 +1.7%	$6.50 +343.7%	-39.1%	$160.43M	$70.39M	N/A	250	Positive News
NAUT Nautilus Biotechnology	2.0999 of 5 stars	$1.02 +2.6%	$4.00 +294.1%	+25.8%	$129.16M	N/A	N/A	130
MXCT MaxCyte	2.832 of 5 stars	$1.19 -0.4%	$5.00 +321.9%	-19.0%	$122.10M	$33.03M	N/A	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors